# PRODUCT INFORMATION



## Tizanidine-d<sub>4</sub> (hydrochloride)

Item No. 26521

CAS Registry No.: 1188263-51-5

Formal Name: 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl-4,4,5,5-d<sub>4</sub>)-

2,1,3-benzothiadiazol-4-amine, monohydrochloride

MF: C<sub>o</sub>H<sub>a</sub>CID<sub>a</sub>N<sub>5</sub>S • HCI

FW: 294.2


**Chemical Purity:** ≥98% (Tizanidine)

Deuterium

Incorporation:  $\geq$ 99% deuterated forms (d<sub>1</sub>-d<sub>4</sub>);  $\leq$ 1% d<sub>0</sub>

Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



### **Laboratory Procedures**

Tizanidine- $d_4$  (hydrochloride) is intended for use as an internal standard for the quantification of tizanidine (Item No. 16477) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Tizanidine-d<sub>4</sub> (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the tizanidine- $d_4$  (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Tizanidine- $d_4$ (hydrochloride) is soluble in organic solvents such as methanol.

#### Description

Tizanidine is an  $\alpha_2$ -adrenergic receptor ( $\alpha_2$ -AR) agonist. Administration of tizanidine reduces neuronal excitation induced by noxious stimuli and depresses spontaneous neuronal firing in anesthetized cats. Tizanidine-induced neuronal depression is reversed by the selective  $\alpha_2$ -AR antagonist RX781094 but not the  $\alpha_1$ -AR antagonists prazosin (Item No. 15023) and WB-4101. It acts as a muscle relaxant that inhibits α- and γ-rigidity in rats, reflex muscle tone in rabbits, and the linguomandibular reflex in cats without sedative, hemodynamic, or neurochemical effects.<sup>2</sup> Formulations containing tizanidine have been used in the treatment of spasticity.

#### References

- 1. Davies, J. and Quinlan, J.E. Neuroscience 16(3), 673-682 (1985).
- 2. Sayers, A.C., Bürki, H.R., and Eichenberger, E. Arzneimittelforschung 30(5), 793-803 (1980).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 05/17/2023

#### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM